Evidence map›Paper›PMID 24769896›Full record

ArticleOncogene2015

Nucleostemin stabilizes ARF by inhibiting the ubiquitin ligase ULF.

D Lo, Y Zhang, M-S Dai, X-X Sun, S X Zeng, H Lu

Abstract read
In one paragraph

Article in Oncogene, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. SIRT7 promotes lung cancer progression by destabilizing the tumor suppressor ARF.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

D LoDepartment of Biochemistry and Molecular Biology, Tulane Cancer Center, Tulane University School of Medicine, New Orleans, LA, USA.
Y ZhangDepartment of Biochemistry and Molecular Biology, Tulane Cancer Center, Tulane University School of Medicine, New Orleans, LA, USA.
M-S DaiDepartment of Molecular and Medical Genetics, Oregon Health and Science University, Portland, OR, USA.
X-X SunDepartment of Molecular and Medical Genetics, Oregon Health and Science University, Portland, OR, USA.
S X ZengDepartment of Biochemistry and Molecular Biology, Tulane Cancer Center, Tulane University School of Medicine, New Orleans, LA, USA.
H LuDepartment of Biochemistry and Molecular Biology, Tulane Cancer Center, Tulane University School of Medicine, New Orleans, LA, USA.
Tulane University · USOregon Health & Science University · US

Funding

The Role of Ribosomal Proteins in the P53-MDM2 PathwayR01CA095441 · NCI · TULANE UNIVERSITY OF LOUISIANA · PI LU, HUA · 2002 to 2021
$5.1M
MOLECULAR DISSECTION OF A NOVEL P53 LIKE PROTEINR01CA079721 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI LU, HUA · 1999 to 2006
$1.8M
Role of Otubain 1 in the p53 PathwayR01CA160474 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI DAI, MU-SHUI · 2012 to 2016
$1.6M
Role of ribosomal proteins in regulating c-MycR01CA129828 · NCI · TULANE UNIVERSITY OF LOUISIANA · PI LU, HUA · 2008 to 2012
$1.5M
Dual Targeting of the p53 pathway for development of anti-cancer therapyR01CA172468 · NCI · TULANE UNIVERSITY OF LOUISIANA · PI LU, HUA · 2012 to 2016
$1.5M
NCI NIH HHS CA079721NCI NIH HHS CA095441NCI NIH HHS CA129828NCI NIH HHS CA172468NCI NIH HHS R01 CA079721NCI NIH HHS R01 CA095441NCI NIH HHS R01 CA129828NCI NIH HHS R01 CA160474NCI NIH HHS R01 CA172468
6 · The paper itself

Abstract

Upregulated expression of nucleolar GTPase nucleostemin (NS) has been associated with increased cellular proliferation potential and tumor malignancy during cancer development. Recent reports attribute the growth regulatory effects of NS protein to its role in facilitating ribosome production. However, the oncogenic potential of NS remains unclear, as imbalanced levels of NS have been reported to exert growth inhibitory effect by modulating p53 tumor-suppressor activity. It also remains in questions if aberrant NS levels might have a p53-independent role in regulation of cell proliferation and growth. In this study, we performed affinity purification and mass spectrometry analysis to explore protein-protein interactions influencing NS growth regulatory properties independently of p53 tumor suppressor. We identified the alternative reading frame (ARF) protein as a key protein associating with NS and further verified the interaction through in vitro and in vivo assays. We demonstrated that NS is able to regulate cell cycle progression by regulating the stability of the ARF tumor suppressor. Furthermore, overexpression of NS suppressed ARF polyubiquitination by its E3 ligase Ubiquitin Ligase for ARF and elongated its half-life, whereas knockdown of NS led to the decrease of ARF levels. Also, we found that NS can enhance NPM stabilization of ARF. Thus, we propose that in the absence of p53, ARF can be stabilized by NS and nucleophosmin to serve as an alternative tumor-suppressor surveillance, preventing potential cellular transformation resulting from the growth-inducing effects of NS overexpression.

Indexed as

Carrier ProteinsCell Line, TumorG1 Phase Cell Cycle CheckpointsGTP-Binding ProteinsHumansNuclear ProteinsProtein StabilityProtein Structure, TertiaryProto-Oncogene Proteins c-mdm2Tumor Suppressor Protein p14ARFTumor Suppressor Protein p53Ubiquitin-Protein LigasesCarrier ProteinsGNL3 protein, humanGTP-Binding ProteinsMDM2 protein, humanNuclear ProteinsProto-Oncogene Proteins c-mdm2TRIP12 protein, humanTumor Suppressor Protein p14ARFTumor Suppressor Protein p53Ubiquitin-Protein Ligases

Identifiers

PMID24769896
PMCPMC4212020
OpenAlexW2009961156

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.